HNN3.0
Register
Register
Register

Project cooperationUpdated on 8 December 2025

Nanolive – Cooperation Profile

CEO at Nanolive

Tolochenaz, Switzerland

About

What We Offer to Horizon Europe Consortia

1. New Approach Methodologies (NAMs) / Alternative to Animal Testing

  • A proven technology to generate human-relevant, functional cellular readouts.

  • Non-invasive measurement of mitochondrial dynamics, cytotoxicity, cell death pathways, and metabolic stress.

  • AI-driven quantitative endpoints aligned with regulatory expectations for mechanism-based NAMs.

2. Advanced Tools for ATMPs

  • Real-time monitoring of stem cells, CAR-T, immune cells, and other ATMPs without labels.

  • Characterization of cell state, activation, viability, proliferation, and quality attributes.

  • Enabling technology for CoEs on ATMPs and next-generation manufacturing workflows.

3. Regulatory Science & Translational Development

  • High-quality datasets that support validation, standardization, and regulatory acceptance of new testing modalities.

  • Expertise in designing robust analytical pipelines for drug discovery and safety assessment.

  • Strong alignment with calls requiring quantitative, reproducible, patient-relevant data.

4. AI-driven Biomedical Research Tools

  • Automated cellular segmentation, lineage tracking, and phenotype classification.

  • Integrations with data science workflows for computational biology and multi-omics pipelines.

  • Experience collaborating with pharma partners (e.g., Sanofi) on predictive safety and efficacy models.

Topic

  • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
  • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential
  • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
  • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-05: Pilot actions for follow-on funding: Leveraging EU-funded collaborative research in regenerative medicine
  • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
  • DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies

Organisation

Nanolive

Company (SME)

Tolochenaz, Switzerland

Similar opportunities

  • Project cooperation

    ForecomAI: Enhanced Image Analysis for Next-Generation NAM Platforms

    • Partner seeks Consortium/Coordinator
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing

    Amaia Irizar

    CEO at ForecomAI

    London, United Kingdom

  • Project cooperation

    AI-Driven Microfluidic 3D In Vitro Platform for Multi-Tissue Crosstalk in Drug Testing

    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing

    MARCO BERZANO

    Research Manager and Advisor - Head of Medical Area at Università Politecnica delle Marche

    Ancona, Italy

  • Project cooperation

    Collaboration: NAMs to advance biomedical research

    • Partner seeks Consortium/Coordinator
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices

    Sarka Lehtonen

    Research Director at A.I.Virtanen Institute for Molecular Sciences

    Kuopio, Finland